Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Rutgers, The State University of New Jersey · Rutgers New Jersey Medical School · +1 more institution
Abstract
The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998-September 2002. Granulomatous infections were reported at rates of approximately 239 per 100,000 patients who received infliximab and approximately 74 per 100,000 patients who received etanercept (P
Citation impact
- FWCI
- 35.25
- Percentile
- 100%
- References
- 28
Authors
5- RSRobert S. WallisCorresponding
Rutgers, The State University of New Jersey, Rutgers New Jersey Medical School
- MSMichael S. Broder
University of California, Los Angeles
- JYJia Yi Karen Wong
University of California, Los Angeles
- MEM. E. Hanson
University of California, Los Angeles
- DODavid O. Beenhouwer
University of California, Los Angeles
Topics & keywords
- Medicine
- Infliximab
- Etanercept
- Internal medicine
- Histoplasmosis
- Tuberculosis
- Gastroenterology
- Adverse effect
- Good health and well-being